MARKET

EARS

EARS

Auris Medical Holding Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7978
+0.0078
+0.99%
After Hours: 0.7899 -0.0079 -0.99% 16:37 09/21 EDT
OPEN
0.7800
PREV CLOSE
0.7900
HIGH
0.7978
LOW
0.7500
VOLUME
116.64K
TURNOVER
--
52 WEEK HIGH
3.040
52 WEEK LOW
0.6500
MARKET CAP
3.68M
P/E (TTM)
-0.3387
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Earnings Recap For The Week Of September 18
It was a relatively quiet week for earnings, with Adobe Inc (NASDAQ: ADBE) and FedEx (NYSE: FDX) being the biggest names to report. Here's a recap. 
Benzinga · 3d ago
Auris Medical +5% on 1H results
Auris Medical (EARS) 1H results ((CHF)): Revenues: 0; Net Loss: (2.7M) improved 27%; Loss Per Share: (0.58) (+65.0%); Quick Assets: 0.04M.On September 8, the Company under product code AM-301 initiated the development of a
Seekingalpha · 4d ago
Auris Medical reports 1H results
Auris Medical (EARS): 1H GAAP EPS of -CHF0.58.Cash and cash equivalents of CHF0.04M.Shares are up 5% PM.Press Release
Seekingalpha · 4d ago
Auris Medical Holding Ltd. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / September 17, 2020/ Auris Medical Holding Ltd.
ACCESSWIRE · 4d ago
Auris Medical to Report First Half 2020 Financial Results and Provide Business Update on Thursday, September 17, 2020
Hamilton, Bermuda, September 11, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that it will provide a business update and report
GlobeNewswire · 09/11 13:00
Auris Medical Launches Development of Drug-Free Nasal Spray for Protection against Airborne Pathogens and Allergens
* Development of AM-301 nasal spray initiated with aim of regulatory submission in 2021 * Key component of AM-301 shown to reduce SARS-CoV-2 viral infectious load in vitro by up to 99% * Creation of dedicated subsidiary, Altamira Medica Ltd, to focus solely on AM-301 development program * CHF 1.5
GlobeNewswire · 09/08 13:30
Auris Medical Highlights Launch Of Drug-Free Nasal Spray For Protection Against Airborne Pathogens, Allergens
Auris Medical Holding Ltd. (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced the
Benzinga · 09/08 12:31
Auris Medical Announces Interim Data From TRAVERS Phase 2 Study With AM-125 in Vertigo; Says Improvement 1.9 To 2.4 Times Greater With Highest Dose Than With Placebo
Dose dependent improvement in balance tests over placebo in Part A of TRAVERS trial Improvement 1.9 to 2.4 times greater with highest dose than with placebo Trial to proceed with Part B to test AM-125 10 and 20 mg
Benzinga · 09/03 12:34
More
No Data
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EARS stock price target is 14.97 with a high estimate of 14.97 and a low estimate of 14.97.
EPS
Institutional Holdings
Institutions: 12
Institutional Holdings: 1.07M
% Owned: 23.31%
Shares Outstanding: 4.61M
TypeInstitutionsShares
Increased
0
0
New
5
14.00K
Decreased
2
11.48K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.94%
Pharmaceuticals & Medical Research
-2.24%
Key Executives
Chairman/Chief Executive Officer/Director
Thomas Meyer
Non-Executive Vice Chairman
James Healy
Chief Financial Officer/Primary Contact
Hernan Levett
General Counsel
Anne Zoller
Other/IR Contact Officer
Cindy McGee
Other
Andrea Braun
Other
Thomas Jung
Other
Bettina Stubinski
Director
Mats Blom
Non-Executive Independent Director
Oliver Kubli
Director
Alain Munoz
Non-Executive Independent Director
Berndt Modig
Non-Executive Independent Director
Armando Anido
Non-Executive Independent Director
Calvin Roberts
Non-Executive Independent Director
Wolfgang Arnold
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More

Analyst Price Target

The average EARS stock price target is 14.97 with a high estimate of 14.97 and a low estimate of 14.97.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About EARS
Auris Medical Holding AG is a Switzerland-based biotechnology company engaged in developing pharmaceutical products for the treatment of inner ear disorders and mental health supportive care. The Company focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The Company operates through subsidiaries in Switzerland, Ireland and the United States.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Auris Medical Holding Ltd stock information, including NASDAQ:EARS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EARS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EARS stock methods without spending real money on the virtual paper trading platform.